Stock Pick

  • This 5-Star Analyst Is Bullish on AMD’s Strong Roadmap

    This 5-Star Analyst Is Bullish on AMD’s Strong RoadmapThe last five years have been one unstoppable ride to the summit for chipmaker Advanced Micro Devices (AMD). Simultaneously closing the gap between its traditionally bigger rivals, Intel and Nvidia, and itself, the CPU/GPU maker is now most definitely a force to be reckoned with.Following an investor call with the company, Nomura analyst David Wong sees no reason to change tack when considering AMD as an investment.The 5-star analyst has a Buy rating on AMD shares to go along with a $64 price target. The implication for investors? Potential upside of 18% from current levels. (To watch Wong’s track record, click here)Behind AMD’s growth has been an exemplary roadmap. Still to come in 2020 is the launch of the highly anticipated Milan data center CPU, the third generation EPYC processor. Add to that the release of a new data center GPU “optimized on CDMA data center optimized architecture,” a new consumer GPU (Big Navi on RDNA 2), and Zen 3 desktop CPUs.AMD has stated its “product cadence” has been “condensed” so that new generations could hit the market every five or six quarters. Desktops and servers are usually first in line, followed by notebooks.“Given that AMD intends to launch a new generation of desktop and server CPUs near the end of 2020 and recently launched a new generation of notebook processors, this cadence implies that there may be a new generation of notebook processors in 2021 and a new generation of desktop and server processors in late 2021, or more likely the first part of 2022,” Wong said.The company’s aim of achieving between 20% to 30% year-over-year revenue growth in 2020 appears to be on track, too. In addition, despite the fact that this quarter’s ramp up of new semi-custom products for next-generation game consoles has had a “temporary impact” on gross margins, the chipmaker’s long-term goal of bringing in gross margins of over 50% hasn’t changed, either.Now let’s take a look at what the rest of the Street currently makes of AMD; Based on 12 Buys and 8 Holds, AMD has a Moderate Buy consensus rating. The analysts forecast a modest upside of 2%, should the $56.56 average price target be met over the next 12 months. (See AMD stock analysis on TipRanks)To find good ideas for tech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * Fulgent Pops 18% In After-Market On FDA Nod For Covid-19 Home Test * Amarin, Apotex Settle Vascepa Dispute; Analyst Stays Sidelined * Groupon Rises After-Hours Despite Revenue Plunging 35% Y/Y * Google and Carrefour Roll Out Voice-Based Shopping Service In France

    from Yahoo Finance https://ift.tt/2C5XkgX

  • 3 ASX growth shares to buy with $3,000

    growth shares

    If you have room in your portfolio for a few growth shares, then I think the three listed below could be top options.

    I believe all three are well-positioned to deliver above-average earnings growth over the next few years and could generate strong returns for investors. Here’s why I’m positive on them and would invest $3,000 across their shares:

    Bubs Australia Ltd (ASX: BUB)

    The first growth share to look at is Bubs. It is a goat’s milk-focused infant formula and baby food company. Whilst I’ve been a fan of Bubs for a while, it is only really now that I think it is investment grade. This is because for a long time its strong sales growth was coming with significant losses. This led to the company burning through cash at a rapid rate. However, Bubs recently reported positive operating cashflow of $2.3 million on record quarterly revenue of $19.7 million. I’m optimistic the company has now reached a scale which will make its operations more and more profitable over the coming years. As a result, I think it could be a good long term option for investors.

    Pro Medicus Limited (ASX: PME)

    Another growth share that I think has a lot of potential is Pro Medicus. This healthcare technology company provides radiology IT software and services to hospitals, imaging centres, and healthcare groups. The product in its portfolio that I’m most excited about is the popular Visage 7 Enterprise Imaging Platform. It delivers fast, multi-dimensional images which are streamed via an intelligent thin-client viewer. Demand for Visage 7 has been strong and the company recently announced a major new contract with one of the highest rated hospitals in the United States. In addition to this, it revealed that it has a number of sales opportunities in its pipeline that it is working on. I believe this bodes well for its future growth.

    Xero Limited (ASX: XRO)

    A final ASX growth share I think investors ought to consider buying is Xero. I think the provider of cloud-based business and accounting software is arguably one of best growth shares on offer on the ASX. This is due to the increasing demand for its platform from small businesses and the stickiness of its product. Combined, they are resulting in significant recurring revenues which I feel are only likely to grow larger in the coming years as more and more businesses move over to the cloud.

    And here are more exciting shares which could be stars of the future…

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    Learn More

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of BUBS AUST FPO and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended BUBS AUST FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 ASX growth shares to buy with $3,000 appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3fqC8Rc

  • AUD/USD Price Forecast – Australian Dollar Continues Choppy Behavior

    AUD/USD Price Forecast – Australian Dollar Continues Choppy BehaviorThe Australian dollar initially tried to rally during the trading session on Tuesday but gave back the gains as soon as we get close to the 0.70 level.

    from Yahoo Finance https://ift.tt/37zPRCu

The Latest